Medical Care
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report 2025
- Dec 02, 25
- ID: 192445
- Pages: 78
- Figures: 74
- Views: 48
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, by Product Form and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
ReveraGen BioPharma
Sperogenix
ReveraGen BioPharma Inc .
Belief BioMed
PTC Therapeutics
Santhera Pharmaceuticals
Italfarmaco
Segment by Type
Exondys
Emflaza
Translarna
Others
Segment by Product Form
Hormonal Drugs
Exon Skipping
Small Molecule Drugs
Others
Segment by Sales Channels
Online Sales
Offline Sales
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Product Form etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, by Product Form and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy (DMD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sarepta Therapeutics
ReveraGen BioPharma
Sperogenix
ReveraGen BioPharma Inc .
Belief BioMed
PTC Therapeutics
Santhera Pharmaceuticals
Italfarmaco
Segment by Type
Exondys
Emflaza
Translarna
Others
Segment by Product Form
Hormonal Drugs
Exon Skipping
Small Molecule Drugs
Others
Segment by Sales Channels
Online Sales
Offline Sales
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Product Form etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.2.5 Others
1.3 Market by Product Form
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Product Form: 2020 VS 2024 VS 2031
1.3.2 Hormonal Drugs
1.3.3 Exon Skipping
1.3.4 Small Molecule Drugs
1.3.5 Others
1.4 Market by Sales Channels
1.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Sales Channels: 2020 VS 2024 VS 2031
1.4.2 Online Sales
1.4.3 Offline Sales
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Home Care
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2020-2031)
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
3.5 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head office and Area Served
3.6 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
3.7 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 ReveraGen BioPharma
11.2.1 ReveraGen BioPharma Company Details
11.2.2 ReveraGen BioPharma Business Overview
11.2.3 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 ReveraGen BioPharma Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.2.5 ReveraGen BioPharma Recent Development
11.3 Sperogenix
11.3.1 Sperogenix Company Details
11.3.2 Sperogenix Business Overview
11.3.3 Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Sperogenix Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.3.5 Sperogenix Recent Development
11.4 ReveraGen BioPharma Inc .
11.4.1 ReveraGen BioPharma Inc . Company Details
11.4.2 ReveraGen BioPharma Inc . Business Overview
11.4.3 ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 ReveraGen BioPharma Inc . Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.4.5 ReveraGen BioPharma Inc . Recent Development
11.5 Belief BioMed
11.5.1 Belief BioMed Company Details
11.5.2 Belief BioMed Business Overview
11.5.3 Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Belief BioMed Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.5.5 Belief BioMed Recent Development
11.6 PTC Therapeutics
11.6.1 PTC Therapeutics Company Details
11.6.2 PTC Therapeutics Business Overview
11.6.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.6.5 PTC Therapeutics Recent Development
11.7 Santhera Pharmaceuticals
11.7.1 Santhera Pharmaceuticals Company Details
11.7.2 Santhera Pharmaceuticals Business Overview
11.7.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.7.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.7.5 Santhera Pharmaceuticals Recent Development
11.8 Italfarmaco
11.8.1 Italfarmaco Company Details
11.8.2 Italfarmaco Business Overview
11.8.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.8.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.8.5 Italfarmaco Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.2.5 Others
1.3 Market by Product Form
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Product Form: 2020 VS 2024 VS 2031
1.3.2 Hormonal Drugs
1.3.3 Exon Skipping
1.3.4 Small Molecule Drugs
1.3.5 Others
1.4 Market by Sales Channels
1.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Sales Channels: 2020 VS 2024 VS 2031
1.4.2 Online Sales
1.4.3 Offline Sales
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Home Care
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2020-2031)
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
3.5 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head office and Area Served
3.6 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
3.7 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031)
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Details
11.1.2 Sarepta Therapeutics Business Overview
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.1.5 Sarepta Therapeutics Recent Development
11.2 ReveraGen BioPharma
11.2.1 ReveraGen BioPharma Company Details
11.2.2 ReveraGen BioPharma Business Overview
11.2.3 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.2.4 ReveraGen BioPharma Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.2.5 ReveraGen BioPharma Recent Development
11.3 Sperogenix
11.3.1 Sperogenix Company Details
11.3.2 Sperogenix Business Overview
11.3.3 Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.3.4 Sperogenix Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.3.5 Sperogenix Recent Development
11.4 ReveraGen BioPharma Inc .
11.4.1 ReveraGen BioPharma Inc . Company Details
11.4.2 ReveraGen BioPharma Inc . Business Overview
11.4.3 ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.4.4 ReveraGen BioPharma Inc . Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.4.5 ReveraGen BioPharma Inc . Recent Development
11.5 Belief BioMed
11.5.1 Belief BioMed Company Details
11.5.2 Belief BioMed Business Overview
11.5.3 Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.5.4 Belief BioMed Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.5.5 Belief BioMed Recent Development
11.6 PTC Therapeutics
11.6.1 PTC Therapeutics Company Details
11.6.2 PTC Therapeutics Business Overview
11.6.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.6.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.6.5 PTC Therapeutics Recent Development
11.7 Santhera Pharmaceuticals
11.7.1 Santhera Pharmaceuticals Company Details
11.7.2 Santhera Pharmaceuticals Business Overview
11.7.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.7.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.7.5 Santhera Pharmaceuticals Recent Development
11.8 Italfarmaco
11.8.1 Italfarmaco Company Details
11.8.2 Italfarmaco Business Overview
11.8.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction
11.8.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
11.8.5 Italfarmaco Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Key Players of Others
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Product Form (US$ Million): 2020 VS 2024 VS 2031
Table 7. Key Players of Hormonal Drugs
Table 8. Key Players of Exon Skipping
Table 9. Key Players of Small Molecule Drugs
Table 10. Key Players of Others
Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Sales Channels (US$ Million): 2020 VS 2024 VS 2031
Table 12. Key Players of Online Sales
Table 13. Key Players of Offline Sales
Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2025)
Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2026-2031)
Table 20. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 22. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 23. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2020-2025)
Table 26. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
Table 27. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 28. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 29. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Headquarters and Area Served
Table 30. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
Table 31. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2026-2031)
Table 37. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 38. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
Table 39. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 40. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2026-2031)
Table 41. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 48. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 49. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 50. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 51. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 52. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 54. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 55. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 56. Sarepta Therapeutics Company Details
Table 57. Sarepta Therapeutics Business Overview
Table 58. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 59. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Sarepta Therapeutics Recent Development
Table 61. ReveraGen BioPharma Company Details
Table 62. ReveraGen BioPharma Business Overview
Table 63. ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 64. ReveraGen BioPharma Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 65. ReveraGen BioPharma Recent Development
Table 66. Sperogenix Company Details
Table 67. Sperogenix Business Overview
Table 68. Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 69. Sperogenix Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Sperogenix Recent Development
Table 71. ReveraGen BioPharma Inc . Company Details
Table 72. ReveraGen BioPharma Inc . Business Overview
Table 73. ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 74. ReveraGen BioPharma Inc . Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 75. ReveraGen BioPharma Inc . Recent Development
Table 76. Belief BioMed Company Details
Table 77. Belief BioMed Business Overview
Table 78. Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 79. Belief BioMed Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Belief BioMed Recent Development
Table 81. PTC Therapeutics Company Details
Table 82. PTC Therapeutics Business Overview
Table 83. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 84. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 85. PTC Therapeutics Recent Development
Table 86. Santhera Pharmaceuticals Company Details
Table 87. Santhera Pharmaceuticals Business Overview
Table 88. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 89. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Santhera Pharmaceuticals Recent Development
Table 91. Italfarmaco Company Details
Table 92. Italfarmaco Business Overview
Table 93. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 94. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Italfarmaco Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Exondys Features
Figure 5. Emflaza Features
Figure 6. Translarna Features
Figure 7. Others Features
Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Product Form (2020-2031) & (US$ Million)
Figure 9. Hormonal Drugs Features
Figure 10. Exon Skipping Features
Figure 11. Small Molecule Drugs Features
Figure 12. Others Features
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Sales Channels (2020-2031) & (US$ Million)
Figure 14. Online Sales Features
Figure 15. Offline Sales Features
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2024 VS 2031
Figure 18. Hospitals Case Studies
Figure 19. Clinics Case Studies
Figure 20. Home Care Case Studies
Figure 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2024 VS 2031
Figure 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2024
Figure 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
Figure 28. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 30. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 34. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Ireland Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2031)
Figure 42. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia & New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 50. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 54. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 58. ReveraGen BioPharma Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 59. Sperogenix Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 60. ReveraGen BioPharma Inc . Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 61. Belief BioMed Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 62. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 64. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Exondys
Table 3. Key Players of Emflaza
Table 4. Key Players of Translarna
Table 5. Key Players of Others
Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Product Form (US$ Million): 2020 VS 2024 VS 2031
Table 7. Key Players of Hormonal Drugs
Table 8. Key Players of Exon Skipping
Table 9. Key Players of Small Molecule Drugs
Table 10. Key Players of Others
Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Sales Channels (US$ Million): 2020 VS 2024 VS 2031
Table 12. Key Players of Online Sales
Table 13. Key Players of Offline Sales
Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2025)
Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2026-2031)
Table 20. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Table 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Table 22. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
Table 23. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2020-2025)
Table 26. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics as of 2024)
Table 27. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2024
Table 28. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 29. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Headquarters and Area Served
Table 30. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Product and Application
Table 31. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2020-2025)
Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2026-2031)
Table 37. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 38. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2020-2025)
Table 39. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 40. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2026-2031)
Table 41. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 43. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 44. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 46. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 47. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 48. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 49. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 50. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 51. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 52. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 54. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 55. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 56. Sarepta Therapeutics Company Details
Table 57. Sarepta Therapeutics Business Overview
Table 58. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 59. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 60. Sarepta Therapeutics Recent Development
Table 61. ReveraGen BioPharma Company Details
Table 62. ReveraGen BioPharma Business Overview
Table 63. ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 64. ReveraGen BioPharma Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 65. ReveraGen BioPharma Recent Development
Table 66. Sperogenix Company Details
Table 67. Sperogenix Business Overview
Table 68. Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 69. Sperogenix Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 70. Sperogenix Recent Development
Table 71. ReveraGen BioPharma Inc . Company Details
Table 72. ReveraGen BioPharma Inc . Business Overview
Table 73. ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 74. ReveraGen BioPharma Inc . Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 75. ReveraGen BioPharma Inc . Recent Development
Table 76. Belief BioMed Company Details
Table 77. Belief BioMed Business Overview
Table 78. Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 79. Belief BioMed Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 80. Belief BioMed Recent Development
Table 81. PTC Therapeutics Company Details
Table 82. PTC Therapeutics Business Overview
Table 83. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 84. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 85. PTC Therapeutics Recent Development
Table 86. Santhera Pharmaceuticals Company Details
Table 87. Santhera Pharmaceuticals Business Overview
Table 88. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 89. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 90. Santhera Pharmaceuticals Recent Development
Table 91. Italfarmaco Company Details
Table 92. Italfarmaco Business Overview
Table 93. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product
Table 94. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025) & (US$ Million)
Table 95. Italfarmaco Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
Table 99. Authors List of This Report
List of Figures
Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Exondys Features
Figure 5. Emflaza Features
Figure 6. Translarna Features
Figure 7. Others Features
Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Product Form (2020-2031) & (US$ Million)
Figure 9. Hormonal Drugs Features
Figure 10. Exon Skipping Features
Figure 11. Small Molecule Drugs Features
Figure 12. Others Features
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Sales Channels (2020-2031) & (US$ Million)
Figure 14. Online Sales Features
Figure 15. Offline Sales Features
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2024 VS 2031
Figure 18. Hospitals Case Studies
Figure 19. Clinics Case Studies
Figure 20. Home Care Case Studies
Figure 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered
Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2024 VS 2031
Figure 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2024
Figure 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2024
Figure 28. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 30. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 34. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Ireland Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2020-2031)
Figure 42. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia & New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 50. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2020-2031)
Figure 54. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 58. ReveraGen BioPharma Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 59. Sperogenix Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 60. ReveraGen BioPharma Inc . Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 61. Belief BioMed Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 62. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 64. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Images Type AIGC Market Research Report 2025
Dec 02, 25
Global Screen Reading Tool for the Blind Market Research Report 2025
Dec 02, 25
Global Full Stack Perception Software Market Research Report 2025
Dec 02, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232